While significant challenges remain, we believe that a derivative of the current tissue engineered heart valve paradigm will ultimately yield a design suitable for clinical evaluation.
These conditions are only part of a complex heart failure-cognition paradigm.
The current review will focus on the role of basic science in investigating primary electrical diseases of the heart as a paradigm for cardiac arrhythmias, concentrating on Brugada syndrome (BrS), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT).
A detailed description of the sampling method and the data collection procedure was given in a related article (Moons P, Van Deyk K, Marquet K, Raes E, De Bleser L, Budts W, De Geest S: Individual quality of life in adults with congenital heart disease: A paradigm shift, under review).
A more puzzling difference is in the lower proportion of patients with coronary heart disease in PARADIGM-HF.
Heart rate in PARADIGM-HF is similar to most other studies except SHIFT (Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial, which mandated a heart rate of ≥70 bpm for inclusion) and SOLVD-T.
Regulation by its nature is about ensuring a minimal acceptable standard; in contrast, bringing ethics into the heart of research paradigms should be about creating a maximal, gold standard of ethical and ethically-conducted research.
LCZ696 is the first ARNI to be tested in patients, and here we describe the design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortalilty and morbidity in Heart Failure trial (PARADIGM-HF).
3, 7, 9 The Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) is testing the hypothesis that LCZ696 200 mg b.i.d is superior to enalapril 10 mg bid is reducing mortality and morbidity in patients with heart failure and reduced ejection fraction (HF-REF).
Patients with chronic HF, NYHA class II IV symptoms, an elevated plasma BNP or NT-proBNP level, and an LVEF of ≤40% were enrolled in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortailty and morbidity in Heart Failure trial (PARADIGM-HF).
